The Oncology Department focuses on the treatment of gastrointestinal tumors, esophageal, and hepatobiliary pancreatic system tumors. Clinical research is employed to advance practical applications, and talent development is instrumental in driving the discipline's progress. Diagnostic and therapeutic services include gastric cancer, colorectal cancer, esophageal cancer, pancreatic cancer, gastrointestinal stromal tumors, neuroendocrine tumors, biliary tract tumors, liver cancer, etc. The department advocates for a multidisciplinary comprehensive approach and individualized treatment for digestive system tumors.
Department Features:
The Oncology Department excels in providing patients with appropriate treatment methods in the areas of drug therapy, comprehensive treatment, and personalized treatment for multiple tumors, including gastric cancer, colorectal cancer, esophageal cancer, pancreatic cancer, biliary tract tumors, liver cancer, gastrointestinal stromal tumors, neuroendocrine tumors, etc. This aims to enhance the clinical benefit and quality of life for patients. Additionally, the department conducts early cancer screening and diagnosis through endoscopy, as well as therapeutic interventions under endoscopic guidance. Moreover, the Digestive Oncology Department is actively involved in clinical research to explore new treatment methods and promote interdisciplinary collaboration.
Technical Collaboration:
NuoLai Medical's Brain Science Clinical Research Center, starting from a foundation of high-end intelligence, digitization, specialization, and globalization, focuses on the research of artificial intelligence and neurobiotechnology. The center aims to further promote the translation of clinical treatment technologies in brain science. It actively engages in the treatment of various brain disorders, including Alzheimer's disease, Parkinson's disease, cerebellar atrophy, cerebral hemorrhage, post-stroke sequelae, and brain functional impairment. The center is dedicated to constructing a specialized treatment system, integrating high-end equipment, and scaling up medical services in the forefront of brain science.
In addition to consolidating and enhancing its existing medical advantages and actively aligning with international cutting-edge medical technology, NuoLai Medical collaborates with domestic experts in cell-targeted treatment technology research and industrialization, including Professor Yan Xiaojun, an academician of the Russian Academy of Engineering. Together, they have initiated a therapeutic cell vaccine engineering project. The participation of Professor Yan's team enhances NuoLai Medical's core competitiveness, completes the prevention loop for major diseases, and particularly establishes distinctive features in the prevention, diagnosis, and rehabilitation of tumors.
NuoLai Medical's Therapeutic Cell Vaccine Engineering Project can achieve precise treatment of liver cancer using T-DC vaccines. This technology weakens the immune-suppressive effects within the tumor microenvironment while enhancing the immune system's ability to target and eliminate cancer cells. It is widely applicable in the preparation of therapeutic vaccines for various cancers, including breast cancer, lung cancer, liver cancer, as well as in the fields of biotechnological treatment for leukemia, brain injuries, and immune system restoration. The technology has obtained authoritative qualification recognition for liver disease treatment from the United States Food and Drug Administration (FDA) and has been granted numerous national invention patents, filling gaps in both international and domestic contexts.